These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 30219989)
1. The value of different Anwar H; Vogl TJ; Abougabal MA; Grünwald F; Kleine P; Elrefaie S; Nour-Eldin NA Ann Nucl Med; 2018 Dec; 32(10):687-694. PubMed ID: 30219989 [TBL] [Abstract][Full Text] [Related]
2. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281 [TBL] [Abstract][Full Text] [Related]
3. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
5. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy. Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011 [TBL] [Abstract][Full Text] [Related]
6. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Satoh Y; Onishi H; Nambu A; Araki T Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma. Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144 [TBL] [Abstract][Full Text] [Related]
9. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer. Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983 [TBL] [Abstract][Full Text] [Related]
12. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of the Volumetric Parameters of Dual-Time-Point Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426 [No Abstract] [Full Text] [Related]
14. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. Liu J; Dong M; Sun X; Li W; Xing L; Yu J PLoS One; 2016; 11(1):e0146195. PubMed ID: 26727114 [TBL] [Abstract][Full Text] [Related]
15. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416 [TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response. Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566 [TBL] [Abstract][Full Text] [Related]
17. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer. Li C; Tian Y; Shen Y; Wen B; He Y AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465 [No Abstract] [Full Text] [Related]
18. Metabolic tumor volume derived from Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Chen HH; Chiu NT; Su WC; Guo HR; Lee BF Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034 [TBL] [Abstract][Full Text] [Related]
20. Primary tumor standardized uptake value (SUVmax) measured on Hui Z; Wei F; Ren H; Xu W; Ren X J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]